Eris rolls out Sundae semaglutide to boost diabetes access 

Key Highlights: 

• Eris Lifesciences has launched its generic semaglutide under the brand Sundae in India, expanding access to GLP-1 therapy for type 2 diabetes and weight management. The company is positioning the launch as a step toward addressing India’s growing diabetes burden while strengthening its advanced metabolic care portfolio 

• Sundae is being introduced in multi-dose vial formats (2 mg/1.5 mL and 4 mg/3 mL) at pricing starting ~₹1,290/month, significantly improving affordability and potentially making GLP-1 therapy accessible to ~70% of India’s diabetes population. Eris also plans to launch a pen-device version in April 2026, priced at ₹4,000–₹4,500/month across strengths, to enhance convenience and adoption 

• With semaglutide gaining traction for its strong glycaemic and weight reduction outcomes, Eris is leveraging its established diabetology network to drive uptake. The addition of Sundae further deepens its chronic care portfolio, aligning with its strategy to expand next-generation diabetes therapies and improve long-term patient outcomes in India 

Implications:  

With Sundae vials starting at ₹1,290 per month and a pen device to follow, Eris is leveraging Natco’s low‑cost manufacturing while using its strong diabetology franchise to push GLP‑1 adoption deep into its chronic care base. 
The launch strengthens Eris’ positioning as a full-spectrum diabetes player—combining oral agents, insulins, and now GLP‑1s—and should support higher share of wallet per patient as semaglutide becomes a core component of advanced metabolic care in India. 

Source: Eris | Image: Eris Lifesciences